Immunome Inc(IMNM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.53 | Insider Own | 8.3% | Shs Outstand | 113.4M | Perf Week | 4.22% |
| Market Cap | 2.21B | Forward P/E | - | EPS next Y | -6.17% | Insider Trans | -6.59% | Shs Float | 108.2M | Perf Month | -14.3% |
| Enterprise Value | 1.70B | PEG | - | EPS next Q | -0.61 | Inst Own | 99.61% | Short Float | 15.97% | Perf Quarter | -18.72% |
| Income | -0.25B | P/S | - | EPS this Y | 3.59% | Inst Trans | -0.6% | Short Ratio | 13.6 | Perf Half Y | -18.26% |
| Sales | 0.00B | P/B | 4.05 | EPS next 5Y | 12.49% | ROA | -59.03% | Short Interest | 17.28M | Perf YTD | -12.66% |
| Book/sh | 4.63 | P/C | 4.24 | EPS past 3/5Y | 7.72% -7.71% | ROE | -64.03% | 52W High | -37.59% ($30.06) | Perf Year | 14.46% |
| Cash/sh | 4.43 | P/FCF | - | Sales past 3/5Y | - | ROIC | -48.02% | 52W Low | 28.14% ($14.64) | Perf 3Y | 114.89% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 18.12% | Gross Margin | - | Volatility(W/M) | 4.6% 5.16% | Perf 5Y | -17.9% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.98 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.08 | EPS Q/Q | -29.43% | Profit Margin | - | RSI (14) | 42.8 | Recom | 1.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.08 | Sales Q/Q | -100% | SMA20 | 0.76% ($18.62) | Beta | 2.67 | Target Price | $35.33 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | -17.97% ($22.87) | Rel Volume | 0.75 | Prev Close | $18.77 |
| Employees | 177 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -26.51% -100% | SMA200 | -16.68% ($22.52) | Avg Volume(3M) | 1.27M | Price | $18.76 |
| IPO | 2020/10/2 | Option/Short | Yes/Yes | Trades | 9002 | Volume | 949,400 | Change | -0.05% |
🧬 This is a US clinical-stage biotech company developing oncology therapeutics. It develops treatments that target cancer using immune-based modalities, including antibodies and antibody-drug conjugates (ADCs), and holds candidates aimed at rare tumors and solid tumors. The company is an oncology biotech advancing into the oncology market with a differentiated antibody discovery platform and a lead candidate in late-stage clinical development.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
Traded less than usual. That is 75% of its average volume.
IMNM has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +3.6% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -17.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 99.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #93 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is IMNM?
IMNM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMNM?
The market cap of IMNM is approximately $2.2B, ranking 1,981 within its sector.
What is the 52-week high and low for IMNM?
IMNM has recorded a 52-week high of $30.06 and a low of $14.64.
